Abbott Laboratories is planning to sell $14.7 billion of bonds in the largest dollar-denominated offering in more than three years as the drug and medical-device maker prepares to split in two.
Through its AbbVie Inc. pharmaceutical unit, Abbott may sell bonds in six parts ranging in size from $500 million to $4 billion, according to a person familiar with the transaction.
The offering is the largest dollar-denominated sale since February 2009, when Roche Holding AG issued $16 billion of debt, Bloomberg data show.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
